

March 26, 2025

Subject Invitation to the 2025 Annual General Meeting (AGM) of Shareholders

To Shareholders of Bioscience Animal Health Public Company Limited

- Enclosures:
1. Copy of the Minutes of the 2024 Annual General Meeting of Shareholders (for Agenda 1).
  2. Annual Report 2024 Form 56-1 One Report (e-One Report) and Statement of financial position Statement of comprehensive income and cash flow statement ended 31 December 2024 in QR CODE format (for consideration of Agenda 2 and 3).
  3. Profiles of the nominated persons to be appointed as directors to replace those who retired by rotation (For the consideration of Agenda 5).
  4. List of independent directors, Proxies for attending the shareholders' meeting.
  5. Proxy Form A, Form B, and Form C as specified by the Department of Business Development set by the Ministry of Commerce (It is recommended to use Form B) for Proxy Form C (only in case of foreign investors who appoint a custodian in Thailand to be a share depository and custodian).
  6. Instructions on how to appoint a proxy, registration, evidence to be presented on the meeting date, voting for the 2024 Annual General Meeting of Shareholders.
  7. Map of the meeting venue.
  8. Company's Articles of Association only in relation to the shareholders' meeting.

As Bioscience Animal Health Public Company Limited ("The Company") will hold the 2025 AGM of Shareholders on Wednesday, April 23, 2025 at 14:00 p.m. at Jupiter Room 13, 1st Floor, Challenger Building, IMPACT Muang Thong Thani, with the agenda as follows:

**Agenda 1 To consider and certify the Minutes of the 2024 AGM of Shareholders**

**Facts and Reasons:** The Company held the Annual General Meeting of Shareholders for the year 2024 on April 24, 2024 and prepared the minutes of the meeting to be sent to relevant agencies. A copy of the minutes of the meeting is enclosed with the notice of this meeting. The details appear in **the document attached number 1.**

**The Board's Opinion:** The recording of the minutes of the meeting is accurate and complete according to the facts. Therefore, it is deemed appropriate to propose that the Annual General Meeting of Shareholders consider certifying the Minutes of the Annual General Meeting of Shareholders for the year 2024 dated April 24, 2024

**Agenda 2 To consider and acknowledge the Company's operating performance for the year 2024**

**Additional information:** The report on the Company's operating performance for the year 2024 appears in the Annual Report 2024 Form 56-1 One Report (e-One Report) in the form of a QR code (QR Code) that has been sent to the holder together with the notice of this meeting. (Details appear in the attachment No. 2).

**Board's Opinion:** Agreed to propose to the Annual General Meeting of Shareholders to acknowledge the Board of Directors' report on the Company's operating results for the year 2024.

**Agenda 3 To consider and approve the statements of financial position, the statements of comprehensive income and cash flows for the year ended at December 31, 2024**

**Facts and Reasons:** According to the provisions of Section 112 of the Public Limited Companies Act B.E. 2535 has required the Board of Directors to provide the statements of financial position, the statements of comprehensive income and cash flows at the end of the company's fiscal year which has been audited by a certified public accountant and proposed to the shareholders' meeting at the annual general meeting to consider and approve.

In this regard, the company has prepared the statements of financial position, the statements of comprehensive income and cash flows for the period ending December 31, 2024, which has been audited by a certified auditor and has been reviewed by the Audit Committee As shown in the Annual Report 2024 Form 56-1 One Report (e-One Report) under the heading Financial Statements ended December 31, 2024 in the form QR Code (QR Code) (details appear in the document attached number 2)

**The Board's Opinion:** It is deemed appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the Statement of Financial Position and Statement of Comprehensive Income for the period ended December 31, 2024 which has been audited by a certified auditor and reviewed by the Audit Committee. exam

**Agenda 4 To consider and approve the dividend payment and set aside legal reserves for the year 2024**

**Facts and Reasons:** The Company has a policy to pay dividends depending on the performance of the business at the rate of not less than 30% of the net profit from the Company's consolidated financial statements and its subsidiaries and considered together with the separate financial statements. After deduction of corporate income tax and the allocation of all types of reserves. Legal reserves will be allocated at a rate of not less than 5% of the net profit from the separate financial statements.

**Opinion of the Board of Directors:** The Board of Directors deems it appropriate to proposed shareholders' meeting to consider and approve the profit apportionment and dividend payment from the company's operating results Y2024 as follows:

At present, the Company has allocated legal reserves of no less than 10 percent of the registered capital of 157.00 million baht, amounting to 15.70 million baht as required by law.

Due in the year 2024, The company has a net profit after income tax according to the consolidated financial statements amount of 71,656,261 baht, it was deemed appropriate to propose to the shareholders' meeting to approve the dividend payment to the shareholders. From the operating period from January 1, 2024 to December 31, 2024 in the form of cash at the rate of 0.14 baht per share, 314,000,000 shares, amounting to 43,960,000 baht, representing 61.35 percent of the net profit of the consolidated financial statements.

The Company has already paid an interim dividend on September 11, 2024 at the rate of 0.05 baht per share for 314,000,000 shares, totaling 15,700,000 baht. The remaining dividend payment from the second half six-month operating period 2024 at the rate of 0.09 baht per share, totaling 28,260,000 baht.

Determining the list of shareholders who are entitled to receive dividends (Record Date) on May 2, 2025 and dividend payment on May 20, 2025. However, the right to pay such dividends is still uncertain until it is approved by shareholders at the 2025 Annual General Meeting of Shareholders.

**Agenda 5 To consider and approve the appointment of directors to replace those who retired by rotation**

**Facts and Reasons:** According to Section 71 of the Public Limited Company Act B.E. 2535 and Article 19 of the Company's Articles of Association Including the Company's Board of Directors Charter Has stipulated that at every annual general meeting of shareholders one-third of the directors shall resign. If the number of directors cannot be divided exactly into three parts, the number of directors closest to one-third shall retire. The directors who retired by rotation may be re-elected. **the document attached number 3.**

At the Annual General Meeting of Shareholders for the year 2025, there are 4 directors who will retire by rotation are listed below,

- |                                 |                       |
|---------------------------------|-----------------------|
| 1. Mr. Vanchai Sriherunrasmee   | Chairman of the Board |
| 2. Mr. Suchat Worrawutthangkool | Director              |
| 3. Mr. Rungroj Thavontanakul    | Director              |
| 4. Mr. Poramase Kampak          | Director              |

Between December 1, 2024, and December 31, 2024, the company announced on its website and notified through the electronic system of the Stock Exchange of Thailand to give shareholders the right to propose individuals they deem qualified according to the specified criteria to be considered for election as directors of the company. However, at the end of the specified period, no shareholders proposed any individuals for consideration as candidates for the company's board of directors.

**The Board's Opinion:** The Board of Directors, excluding interested directors, has carefully and prudently considered that the directors nominated for this term possess qualifications suitable for the company's business operations. In doing so, they have taken into account compliance with relevant criteria, experience, expertise, ethics and integrity, a transparent work history, and performance results. The company deems it appropriate to propose to the Annual General Meeting of Shareholders the reappointment of the 4 directors whose terms have expired for another term.

**Agenda 6 To consider and approve the directors' remuneration for the year 2025**

**Facts and Reasons:** The Board of Directors has considered the remuneration and a meeting allowances for company directors and sub-committees considering the suitability of the type of business company, business growth rate as well as the duties and responsibilities of the directors.

**Board's Opinion :** The Board of Directors considered and unanimously agreed to propose to the AGM of Shareholders to consider and approve the remuneration. which is the same rate as 2024, Additionally, there will be an increase in the remuneration for the company's directors and the Risk Committee members for non-executive directors. The details of the remuneration for the directors and sub-committees are as follows:

Monthly Remuneration for Directors

Position	Remuneration for Directors (baht per month)	
	2025	2024
Chairman of the Board	25,000	25,000
Director	20,000	-
Chairman of the Audit Committee	25,000	25,000
Audit Committee/Independent	20,000	20,000

Board meeting allowance

Position	Meeting allowance (baht per time)	
	2025	2024
Chairman of the Board	20,000	20,000
Director	15,000	-
Independent Director	15,000	15,000

In this regard, the Board of Directors who are executives of the Company will not request monthly remuneration and meeting allowances for the Board of Directors

Audit Committee and the Risk Management Committee meeting allowance

Position	Meeting allowance (baht per time)	
	2025	2024
Chairman of the Audit Committee	20,000	20,000
Audit Committee	15,000	15,000
Chairman of the Risk Management Committee	15,000	15,000
Risk Management Committee	10,000	-

In this regard, the Board of Directors who are executives of the Company will not request monthly remuneration and meeting allowances for the Board of Directors

**Agenda 7 To consider the appointment of the auditor and determine the audit fee for the year 2025**

**Facts and Reasons:** In order to comply with the Public Limited Companies Act B.E. 2535, Section 120, The shareholders' meeting is required to appoint company's auditor and determine the auditor's remuneration every year. And according to the regulations of the Securities and Exchange Commission (SEC) requires companies that issue securities to which is a listed company on the Stock Exchange of Thailand must provide auditor rotation every 7-year accounting period.

**Opinion of the Board of Directors :** The Audit Committee has been considering the qualifications of auditors and audit fee that in Y2024, Baker Tilly Audit and Advisory Services (Thailand) Ltd. is an experienced auditor firm, which are famous and generally accepted. The three of nominated auditors are not contrary to the SET, no relationship with, or any interest with the Company, Executives, major shareholders or any related persons, which may have an impact on performing tasks independently. The Board of Directors shall ensure that the Auditor can perform it tasks in time.

List of auditor name proposed by Baker Tilly Audit and Advisory Services (Thailand) Ltd.

Auditor	Certified Public Accountant registration number	Years of auditing the Company
Mr. Apichart Sayasit	4229	3 Years
Ms. Wimon Sri Jongudomsombat	3899	3 Years
Ms. Waleerat Akraisawat	4411	-

If the aforementioned auditors are unable to perform their duties, Baker Tilly Audit and Advisory Services (Thailand) Co., Ltd. procures other certified auditors of the firm auditing and expressing opinions on the Company's financial statements in place of such auditor.

In 2025, the audit fee will be settled at the total of 3,460,000 Baht per year which not include other expenses that are actually charged. Which decreased from the previous year by 957,351 Baht, or a percentage of 21.67% (In 2024, the audit fee was 4,417,351 Baht).

Comparison Table of Audit Fees for the Year 2024 - 2025

Audit Fee	2025	2024	Increased (Decreased)
The audit fee for the company's financial statements	1,335,000	1,335,000	-
The audit fee for the subsidiary's financial statements	2,125,000	3,082,351	(957,351)
<b>Total</b>	<b>3,460,000</b>	<b>4,417,351</b>	<b>(957,351)</b>

Note : - In 2024 Baker Tilly Audit and Advisory Services (Thailand) Co., Ltd. was the auditor for the company and its subsidiaries in Thailand with an audit fee of 3,880,000 Baht and The Right Partner Consulting Group co., LTD was the auditor for the subsidiaries abroad with an audit fee of 537,351 Baht. The total audit fee amounts to 4,417,351 Baht

- In 2025 Baker Tilly Audit and Advisory Services (Thailand) Co., Ltd. will be the auditor for the company and its subsidiaries both in Thailand and abroad, proposing an audit fee mounts to 3,460,000 Baht

The Company and its subsidiaries Use the same auditing office "The committee will ensure that financial statements can be prepared in a timely manner."

#### Agenda 8 Consider other matters (if any)

-

The Company has set the date for determining the names of shareholders who are entitled to attend the 2025 AGM of Shareholders (Record Date) on Friday, March 14, 2025. The Company has published this Notice of the 2025 AGM of Shareholders along with meeting documents and proxy form on the company's website [www.bis-group.com](http://www.bis-group.com) in the section "Shareholders' Meeting".

In this regard, the shareholders are hereby invited to attend the meeting on the date, time and place mentioned above. The company has prepared a map of the meeting venue according to **the document attached number 7**, and for the convenience and speed of registration for attending the Annual General Meeting of Shareholders, the Company will arrange for the registration of attendees from 13:00 p.m. onwards. The company will conduct the meeting in accordance with the company's regulations as detailed in **the document attached number 8**.


If any shareholder wishes to appoint another person to attend the meeting and vote on their behalf in this meeting please fill in the details and sign the proxy form attached to the invitation to this meeting as per **document attached number 5**. The company recommends using a Proxy Form B, which you can specify voting clearly. However, the Company has attached Proxy Form A (general form which is a simple and uncomplicated form) and Proxy Form C (form used only in case the shareholder is a foreign investor and appoints Custodian (Custodian) in Thailand is a custodian and takes care of shares) for shareholders to choose as appropriate.

If any shareholder wishes to appoint an independent director of the Company as a proxy you can find details of the profiles of independent directors who are assigned as proxies for shareholders who are unable to attend the meeting in **the document attached number 4**. Designated as this proxy, he has no special interest in the agenda proposed in this meeting in any way, except for Agenda 6 on consideration and approval of the remuneration of directors for the year 2025.

In order for shareholders to get the most from the meeting as well as to fully protect the rights of shareholders, the Company requests shareholders or proxies to prepare supporting documents for meeting registration. Shareholders are ready to bring the registration form for attending the 2025 Annual General Meeting of Shareholders (with Bar Code) to present for registration on the meeting date. In this regard, please proceed to study the rules for attending the meeting consisting of how to appoint a proxy meeting registration evidences to be presented on the meeting date and how to vote For the shareholders' meeting as specified in **the document attached number 6** and in the event that shareholders have questions that they would like the Company to clarification on the above agenda please send your questions in advance by April 10, 2025, including your name, address, telephone number and e-mail address (if any) that can be contacted via e-mail [info@bis-group.com](mailto:info@bis-group.com)

Please be informed accordingly.

Yours sincerely,



(Mr. Vanchai Sriherunrusmee)

Chairman of the Board

**Bioscience Animal Health Public Company Limited**  
**Minutes of the 2024 Annual General Meeting of Shareholders**

Date, time and place

The meeting was held on April 24, 2024 at 9:30 a.m. at Jupiter Room 13, 1st Floor, Challenger Building, IMPACT Muang Thong Thani, Popular Road, Ban Mai Subdistrict, Pak Kret District, Nonthaburi Province.

Start a meeting

Before entering the meeting agenda, the meeting moderator gave a welcome speech and informed the meeting that at the annual general meeting for the year 2024, the Company uses the barcode system for registration and vote counting. Then Ms. Natnicha Priewpanich, the investor relations of the company Informed the meeting about the details and criteria for voting and how to count the votes in the meeting as well as in the event that the card is considered invalid. In addition, before voting on each agenda, an opportunity is given to the meeting participants to ask questions related to that agenda as appropriate. The names and surnames of shareholders or proxies must be informed before asking questions or expressing opinions every time. And for the vote counting to be transparent, the company provided a vote counting witness, Mr. Thana Chaopanitchakool, witnessed the vote counting in this meeting.

Mr. Vanchai Sriherunrusmee, the Chairman opened the 2024 Annual General Meeting of Shareholders. At the beginning of the meeting, there were shareholders and proxies attending the meeting was as follows: 23 people came in person with a total of 85,746,980 shares and 16 proxies with a total of 126,241,300 shares, total shareholders was 39 proxies attended the meeting, totaling 211,988,280 shares, accounting for 67.51 percent of the total number of shares sold of the Company. The quorum was constituted according to the Company's Articles of Association, Chapter 5, Article 38.

In this regard, the meeting facilitator introduced the directors, executives, legal advisors and auditors attending the Company's meetings which consists of,

Directors attending the meeting as follows:

- |                                      |  |
|--------------------------------------|--|
| 1. Mr. Vanchai Sriherunrusmee        | Chairman of the Board,   |
| 2. Honorary Prof. Rajata Rajatanavin | Independent Director,<br>Chairman of the Audit Committee                           |
| 3. Prof. Dr. Thaweesak Songserm      | Independent Director, Audit Committee<br>Chairman of the Risk Management Committee |
| 4. Assoc. Prof. Dr. Jade Donavanik   | Independent Director, Audit Committee  |
| 5. Mr. Dhanawat Khongjaroensombat    | Director, Chairman of Executive Board  |

- |                                 |  |
|---------------------------------|--|
| 6. Mr. Suchat Worrawutthangkool | Director, Chief Executive Officer,<br>Risk Management Committee                            |
| 7. Mr. Poramase Kampak          | Director, Chief Operating Officer,<br>Risk Management Committee                            |
| 8. Mr. Rungroj Thavontanakul    | Director, Chief Administrative Officer,<br>Risk Management Committee,<br>Company Secretary |

**Executives attending the meeting are as follows:**

- |                              |                         |
|------------------------------|-------------------------|
| 1. Mr. Paphon Sirichotikul   | Chief Financial Officer |
| 2. Ms. Nareerat Chatkunakorn | Accounting Manager      |
| 3. Mr. Saran Chatyanon,      | Executive Director      |

**Legal Advisor from KPMG Phoomchai Audit Ltd.**

- |                              |               |
|------------------------------|---------------|
| 1. Mr. Puchong Chairungreang | Legal Advisor |
|------------------------------|---------------|

**Auditor from Baker Tilly Audit and Advisory Services (Thailand) Ltd.**

- |                                |                             |
|--------------------------------|-----------------------------|
| 1. Mr. Apichart Sayasit        | Certified Public Accountant |
| 2. Ms. Wimolsri Jongudomsombut | Certified Public Accountant |
| 3. Ms. Bunnarach Punnarach     | Certified Public Accountant |
| 4. Ms. Nantika Phukpianlert    | Assistant Auditor           |

The Company had provided an opportunity for shareholders to propose matters for inclusion in the agenda of the AGM Y2024 during on December 1-31, 2023. However, after the end of such period, none of the shareholders proposed any matter for inclusion in the agenda.

**Agenda 1 To consider and certify the Minutes of the 2023 Annual General Meeting of Shareholders**

The Chairman proposed the minutes of the 2023 Annual General Meeting of Shareholders held on April 24, 2023 to the meeting for approval. A copy of the minutes of the meeting is enclosed with the notice of this meeting. The details appear in the document, Enclosure No. 1 which has been sent to all shareholders along with the meeting invitation letter.

The moderator then gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered in detail. It was found that the minutes of the 2023 Annual General Meeting of Shareholders were accurate and complete. Resolved to certify the minutes of the 2023 Annual General Meeting of Shareholders held on April 24, 2023 with the following votes:

Shareholders	Number of votes (votes)	Percentage
Agree	218,899,680	100
Disagree	0	-
Abstain	0	-
Bad card	0	-
<b>Total</b>	<b>218,899,680</b>	<b>100</b>

**Note:** 1. A resolution on this agenda must be approved by a majority vote of the shareholders who attend the meeting and vote.

2. In this agenda, there were 4 additional shareholders attending the meeting, representing 6,911,400 shares (total of 43 attendees), totaling 218,899,680 shares in this agenda, representing 69.71 percent of the sold shares all of the company.

**Agenda 2 To consider and acknowledge the Company's operating results for the year 2023**

The chairman at the meeting assigned Mr. Suchat Worrawutthangkool, Chief Executive Officer of the Company mentioned an overview of the company's operating results for the year 2023 ended December 31, 2023

- Operating results for the year 2023, the company had operating income of 2,412.40 million baht, an increase of 9.93 percent.
- Launch of the product LYPOTECH EC, a nutritional supplement for animals.
- The company's pet business It has grown 25 percent in the past year.
- Invest in Vietnam. By purchasing 15 % additional shares in order to increase product distribution channels veterinary services.

Then Mr. Suchat Worrawutthangkool assigned Mr. Paphon Sirichotikul, Chief Financial Officer, to Report the operating results for 2023 to the meeting.

The Company has sales revenue for the year ended December 31, 2023, amounted to THB 2,412.40 million, increased by THB 217.98 million or 9.93% from the previous year. The increasing of overall of sales revenue came from the ASF pandemic situation is ongoing recovery.

Gross profit for the year ended December 31, 2023 and 2022 was THB 332.80 million and THB 316.95 million respectively, the gross profit increased by THB 15.85 million or 5.00% from the previous year. However, the gross profit margin decreased slightly representing a respective gross profit margin of 13.80% and 14.44% respectively. However, the management has control over the ratio of expenses to sales. The proportion of expenses to sales in 2023 is equal to 11.50%.

Net profit for the year ended December 31, 2023 and 2022 amounted to THB 52.88 million and THB 59.67 million respectively, representing a respective net profit margin of 2.18% and 2.69%.

Statement of financial position The company has total assets of THB 1,228.1 million, an increase of 13.2% from the previous year. This was caused by higher trade receivables as sales increased. and inventories reserved for increased sales.

Shareholders' equity as of December 31, 2023 increased by THB 21.96 million or 2.86% from the end of 2022. The company has good financial status and financial liquidity. The profit rate decreased slightly, ROE was at 6.8% and ROA was at 4.6%. This was due to the company's net profit decreasing in the past year.

Mr. Rungroj Thavontanakul, Company Secretary Clarified that the report on the Company's operating results for the year 2023 appears in the 2023 Annual Report (Form 56-1 One Report) in the form of a QR code sent to shareholders together with invitation letter for this meeting (Details appear in the document Enclosure No. 2).

The company is committed to combating dishonesty and corruption. By specifying that the company includes all persons involved in conducting business in all departments. Follow the anti-fraud and corruption policy. and open channels for reporting clues or complaints along with guidelines for protection. In 2023, the company has implemented the policy. continuously for example, the company has posted an announcement. and disseminated through the intranet platform and the company's website. To communicate anti-corruption policies and measures, including laws or other regulations related to such matters to directors, executives, and employees in order to create an understanding of anti-corruption policies. Guidelines and methods for reporting clues and complaints from ongoing illegal actions and there were no complaints from both internal and external parties.

*Mr. Kan Charitana, a shareholder,* thanked the board of directors and executives for the good performance in 2023 and asked that the company's ROE is currently at 6 percent, which is close to the return on investment. Fixed deposit with bank How does the company plan to increase ROE in the future?

*Mr. Paphon Sirichotikul, Chief Financial Officer* Explained that in the past year the ROE value had decreased. This is mainly due to a decrease in net profit margins. In 2024, the company has planned a strategy to increase profit margins by increasing sales from product groups with higher gross margins. Including products from the company's factories that have high gross margins.

*Mr. Suchat Worrawutthangkool, Chief Executive Officer* Further clarified that in 2024 the company has adjusted its business plan and set its 3-year strategy in advance. Focusing on increasing gross profit margins From selling products under the company's brands Increasing the proportion of revenue from the pet business, which is a growing business and diversify business risks among CLMV countries, which will lead to increased profits.

*Mr. Sarun Chatyanon, Executive Director* Further clarified that in the pet business The compound annual growth rate (CAGR) is approximately 10 percent. The company's past performance has seen sales grow at approximately 2 times the CAGR. The company has a direction and strategy to increase revenue from products that Produced and distributed under the company's brand. This will be an important part in increasing the company's gross profit margin.

When it appeared that there was no shareholder commenting and asking any additional questions, the meeting acknowledged the Company's operating results for the year 2023 ending December 31, 2023 as proposed and since it was an agenda for acknowledgment, no resolution required.

**Agenda 3 To consider and approve the statement of financial position statement of comprehensive income and cash flow statement which has been audited by the auditor for the year ended December 31, 2023**

The Chairman announced to the meeting that the Company has prepared financial statements for the fiscal year ended December 31, 2023, which have been reviewed by the Audit Committee and has been audited and certified by the Company's certified auditor and proposed to the meeting for consideration. Statement of Comprehensive Income and cash flow statement ending December 31, 2023 as shown in the 2023 Annual Report (Form 56-1 One Report). In the topic of financial statements for the period ended December 31, 2023 in the form of QR Code (Details appear in the document Enclosure No. 2) which has been sent to all shareholders together with the invitation letter. The moderator then gave the meeting an opportunity to express their opinions and ask questions related to this agenda.

*Mr. Kan Charity, a shareholder*, had a question

1. Will negative cash from operations over the past two years have an impact on the future?

2. Increase in trade receivables Caused by debt repayment problems or has the company extended the deadline for repayment?

*Mr. Paphon Sirichotikul, Chief Financial Officer* Clarified that the company conducts buying and selling business (Trading), cash from operations is related to trade receivables. Inventories and trade creditors However, due to the outbreak of African Swine Fever (ASF) in 2022, the financial position of some trade debtors worsened. In 2023, the situation is likely to improve accordingly. However, the company There is strict control over debtors. And most of the payment periods are within the specified period. In addition, the value of receivables is regularly followed up in the executive committee meetings.

*Mr. Vanchai Sriherunrusmee, Chairman of the Board* Further clarified that Trade accounts receivable of the company That grew by more than 10 percent due to the economic situation facing the COVID-19 outbreak and the sale of fish products, which causes more trade receivables. At present, this problem has been resolved.

When there were no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered Resolved to approve the statement of financial position, statement of comprehensive Income and cash flow statement of the Company for the accounting period ending December 31, 2023 with the following votes:

Shareholders	Number of votes (votes)	Percentage
Agree	218,908,980	100
Disagree	0	-
Abstain	0	-
Bad card	0	-
<b>Total</b>	<b>218,908,980</b>	<b>100</b>

**Note:** 1. A resolution on this agenda must be approved by a majority vote of the shareholders who attend the meeting and vote.

2. In this agenda, there was 1 additional shareholder attending the meeting, representing 9,300 shares (total of 44 attendees), totaling 218,908,980 shares in this agenda equivalent to 69.72 percent of shares sold of the Company.

**Agenda 4 To consider and approve the dividend payment and set aside legal reserves for the year 2023.**

The meeting facilitator explained to the meeting that the Company has policy to pay dividends depending on the performance of the business at the rate of not less than 30% of the net profit from the consolidated financial statements of the Company and its subsidiaries (Consolidated) and consider together with the separate financial statements. After deduction of corporate income tax and the allocation of all types of reserves. Legal reserves will be allocated at a rate of not less than 5% of the net profit from the separate financial statements.

The Chairman informed the meeting to consider the dividend payment for the operating results for the year 2023 at the rate of 0.11 baht per share, 314,000,000 shares, amounting to 34,540,000 baht, representing 65.32 percent of the net profit of the consolidated financial statements. The Company has already paid an interim dividend on September 8, 2023 at the rate of 0.04 baht per share for 314,000,000 shares, totaling 12,560,000 baht. The remaining dividend payment from the second half six-month operating period 2023 at the rate of 0.07 baht per share, totaling 21,980,000 baht. Determining the list of shareholders who are entitled to receive dividends (Record Date) on May 3, 2024 and dividend payment on May 21, 2024.

The meeting facilitator gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered resolved to approve the allocation of legal reserves and dividend payment for the Company's performance For the accounting period ending December 31, 2023 with details as proposed with the following votes:

Shareholders	Number of votes (votes)	Percentage
Agree	218,908,980	100
Disagree	0	-
Abstain	0	-
Bad card	0	-
<b>Total</b>	<b>218,908,980</b>	<b>100</b>

**Note:** A resolution on this agenda must be approved by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 5 To consider and approve the appointment of directors to replace those who retired by rotation.**

In order to comply with good corporate governance principles, the meeting facilitator invited the directors of the Company who retire under this agenda leaving the meeting room during consideration.

The meeting facilitator further explained to the meeting that according to section 71 of the public company act B.E. 2535 and article 19 of the Company's articles of association including the board of directors' charter, every time One-third of the directors shall resign. If the number of directors cannot be divided exactly into three parts, the number of directors closest to one-third shall retire. Directors retiring by rotation may be re-elected.

At the 2024 Annual General Meeting of Shareholders, there are 2 directors who will retire by rotation. The profiles and information of the directors nominated for appointment this time appeared according to the document Attachment No. 3 that the Company has sent to all shareholders along with the meeting invitation letter. There are 2 persons who are qualified to be independent directors of the Company with 2 directors who retired by rotation in 2024 as follows:

- |                                 |                      |
|---------------------------------|----------------------|
| 1. Prof. Dr. Thaweesak Songserm | Independent Director |
| 2. Dr. Somjin Sornpaisarn       | Independent Director |

In this regard, the moderator additionally clarified to the meeting that the 2 directors consisted of 2 persons qualified as independent directors, namely (1) Prof. Dr. Thaweesak Songserm and (2) Dr. Somjin Sornpaisarn, who can express opinions independently and in accordance with relevant criteria.

Then, the meeting facilitator gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered in detail. It was unanimously resolved to approve the re-appointment of 2 directors who retired by rotation to serve as directors for another term with a majority vote of the shareholders who attended the meeting and voted as follows:

## 1. Prof. Dr. Thaweesak Songserm Independent Director

Shareholders	Number of votes (votes)	Percentage
Agree	218,673,980	100
Disagree	0	-
Bad card	0	-
<b>Total</b>	<b>218,673,980</b>	<b>100</b>
Abstain	235,000	-

**Note:** The abstention vote belongs Prof. Dr. Thaweesak Songserm in the amount of 235,000 shares, was not used as the basis for calculating the percentage.

## 2. Dr. Somjin Sornpaisarn Independent Director

Shareholders	Number of votes (votes)	Percentage
Agree	218,673,980	100
Disagree	0	-
Bad card	0	-
<b>Total</b>	<b>218,673,980</b>	<b>100</b>
Abstain	235,000	-

**Note:** The abstention vote belongs Dr. Somjin Sornpaisarn, totaling 235,000 shares, was not used as the basis for calculating the percentage.

**Agenda 6 To consider and approve the remuneration of directors for the year 2024.**

The Chairman proposed the meeting to consider and approve the remuneration, meeting allowance and remuneration for the directors of the Company's directors and sub-committees of the company for the year 2024, taking into account the suitability company growth rate as well as the duties and responsibilities of the directors Details are as follows:

Monthly Remuneration for Directors

Position	Remuneration for Directors
Chairman of the Board	25,000 baht per month
Director	-
Chairman of the Audit Committee	25,000 baht per month
Audit Committee/Independent	20,000 baht per month

Board meeting allowance

Position	Meeting allowance
Chairman of the Board	20,000 baht per time
Independent Director	15,000 baht per time

Audit Committee and the Risk Management Committee meeting allowance

Position	Meeting allowance
Chairman of the Audit Committee	20,000 baht per time
Audit Committee	15,000 baht per time
Chairman of the Risk Management Committee	15,000 baht per time
Risk Management Committee	-

In this regard, the Board of Directors who are executives of the Company will not request monthly remuneration for directors and meeting allowances for the Board of Directors.

In addition to the remuneration that the directors receive in cash the Company has provided compensation and other benefits such as liability insurance for directors and senior executives. The sum insured amounts to 50,000,000 baht, representing a premium of 107,428 baht per year.

The moderator then gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered resolved to approve the directors' remuneration, meeting allowance and remuneration for directors for company directors and sub-committees of the company for the year 2024 which is the same rate as 2023 with details as proposed with the following votes:

Shareholders	Number of votes (votes)	Percentage
Agree	218,908,980	100
Disagree	0	-
Abstain	0	-
Bad card	0	-
<b>Total</b>	<b>218,908,980</b>	<b>100</b>

**Note:** A resolution on this agenda must be approved by a vote of not less than two-thirds of the shareholders attending the meeting.

**Agenda 7 To consider the appointment of the auditor and determine the audit fee for the year 2024.**

The moderator clarified to the meeting that in order to comply with the Public Limited Companies Act B.E. 2535, Section 120 which requires the shareholders' meeting to appoint and determine the auditor's remuneration every year and according to the regulations of the Office of the Securities and Exchange Commission (SEC) requiring companies that issue securities which is a listed company on the Stock Exchange of Thailand must arrange for auditor rotation every 7 year accounting period.

The Chairman invited Mr. Paphon Sirichotikul, Chief Financial Officer, to clarify this agenda, Mr. Paphon Sirichotikul proposed to the Annual General Meeting of Shareholders to consider and approve Baker Tilly Audit and Advisory Services (Thailand). ) Co., Ltd. as the Company's auditor for the year 2024 and proposed to approve the audit fee for the year 2024 in the amount of 3,825,000 Baht per year which not include other expenses that are actually charged. This increased from the audit fee in 2023 in the amount of 181,000 baht or equal to 4.97 percent. In this regard, one of the following persons from Baker Tilly Audit and Advisory Services (Thailand) Co., Ltd. will be inspected, commented and signed in the company's financial statements.

Auditor	Certified Public Accountant registration number
Mr. Apichart Sayasit	4229
Ms. Wimonstri Jongudomsombat	3899
Ms. Waleerat Akraisawat	4411

The meeting facilitator gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered Resolved to approve the appointment of the company's auditor, and determine the auditor's remuneration for the year 2024 with details as proposed, with the following votes

Shareholders	Number of votes (votes)	Percentage
Agree	218,908,980	100
Disagree	0	-
Abstain	0	-
Bad card	0	-
<b>Total</b>	<b>218,908,980</b>	<b>100</b>

**Note:** A resolution on this agenda must be approved by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 8 Consider other matters (if any).**

The meeting facilitator explained to the meeting that the agenda proposed for consideration as specified by the Company in the notice of the 2024 Annual General Meeting of Shareholders had been considered and gave the opportunity to shareholders to express their opinions and asked questions about other matters in this agenda, with shareholders asking questions as follows:

*Mr. Kan Charity, a shareholder, had a question:*

1. How will the business handle the risk associated with foreign exchange rates?
2. What plan does the business have in place to handle an economic downturn?

*Mr. Vanchai Sriherunrusmee, Chairman of the Board explained that*

1. Regarding the risk of foreign currency exchange rates, the Company has no policy to speculate on exchange rates. The Company will purchase exchange rates approximately not more than 1 month in advance. However, because the Company Carrying out import business and distribute medical supplies products and

products for animals from abroad Product costs may be affected by exchange rates. The company Can adjust the selling price according to the increased product costs.

2. If there is a crisis or situation of economic fluctuation It will affect every company. The company There is tight cost control. together with the company Has a relatively low debt burden This can be observed from the debt to equity ratio (Debt to Equity Ratio) being less than 1 percent. If a crisis occurs, the company will still have cash flow to operate the business in the long term.

*Mr. Krit Wongsomboon, proxy Thai Investors Association* There is a question that from the company There is a relatively large increase in inventory, with a value of 420,000 baht in 2022 and an increase to 3,611,000 baht in 2023. What are the guidelines for managing inventories?

*Mr. Paphon Sirichotikul, Chief Financial Officer* Clarified that the increase in inventory value was due to the stocking of products for sale following higher product sales. This is a normal part of the company's business. The increased inventory came from finished goods owned by the subsidiary. However, the increased value does not have a significant impact on the Company.

*Mr. Vanchai Sriherunrusmee, Chairman of the Board* further clarified that inventory increased by 10% in line with increased sales. It is a normal part of doing business.


*Mr. Krit Wongsomboon, proxy Thai Investors Association* There are additional questions: Regarding organizing a general meeting of shareholders, the company has a policy of holding a hybrid meeting. Or electronically or not?

*Mr. Vanchai Sriherunrusmee, Chairman of the Board* explained that there was consideration at the Board of Directors' meeting. Organizing a meeting in a hybrid format involves complicated procedures and relatively high costs. Therefore, an onsite format is being considered. But if in 2024 the company has increased profits as targeted, it will consider hybrid meetings.

*Mr. Krit Wongsomboon, proxy Thai Investors Association* There was a question about the ESG project that the Stock Exchange is trying to encourage listed companies to participate in. How has the company made progress in implementing the project?

*Mr. Dhanawat Khongjaroensombat, Chairman of Executive Board* explained that the ESG project is in the company's operational plan. The management and executives have given importance to and is in the process of studying to plan to do concrete ESG matters and have positive effects on all stakeholder groups of the company within 3 years. The company Some things have already begun to be done, such as giving advice to farmers on installing solar roofs for livestock farms. and measures to separate waste in the office.

As there were no shareholders expressing their opinions and asking any further questions, the Chairman thank all shareholders for taking their time to attend the meeting and declared the meeting adjourned at 11:15 a.m.



sign.....

(Mr. Vanchai Sriherunrusmee)

Chairman of the meeting



sign.....

(Mr. Rungroj Thavontanakul)

Company Secretary

QR code for download Annual Report 2024 Form 56-1 One Report (e-One Report) and Financial Statements  
Ended December 31, 2024



Using a QR Code (QR Code) for downloading the 2024 Annual Report Form 56-1 One Report  
(e-One Report) and Financial statements for the year ended 31 December 2024

Shareholders can download information via QR Code (as shown in Attachment No. 2) in accordance with the following steps.

**For iOS system (iOS 11 and above)**

1. Open the camera (Camera) on the phone.
2. Scan QR Code
3. The screen will have a message. (Notification) up to the top, press on that message.

Note: In case there is no message (Notification) on mobile phones, shareholders can scan the QR Code from other applications such as QR CODE READER, Facebook and Line etc.

**For Android system**

1. Open the application QR CODE READER, Facebook or Line.

Procedure for scanning QR Code via Line

- Enter the Line application and select Add friend (add friends).
- Select QR Code

2. Scan QR Code

## Profiles of the directors proposed for appointment

### 1. Mr. Vanchai Sriherunrusmee Age 65 Years



**Director**

**Chairman of the Board**

**Shareholding Proportion (As of Dec 31, 2024)**

- direct 0.12%
- indirect 2.31%

**Family relationship between executives:** - None -

**Duration of Directorship : 4 Years** (26 Feb 2021 – Present)

#### Educational qualifications

- Master of Business Administration (M.B.A.), Long Island University, New York
- Advanced Certificate in Accounting, Thammasat University
- Bachelor's Degree in Accounting, Thammasat University
- Certified Public Accountant (CPA)

#### Director training history

- Director Certification Program (DCP) Class 29, 2003
- Role of the Chairman Program (RCP) Class 52, 2022
- Capital Market Academy Program (CMA) Class 5
- Thammasat University for Society Program (NMT) Class 2

#### work experience

##### **Listed Company (2 EA.)**

- |                  |                                 |   |
|------------------|---------------------------------|---|
| • 2021 – Present | Chairman of the Board           | Bioscience Animal Health Public Company Limited |
| • 2023 – Present | Director                        | Bioscience Animal Health Public Company Limited |
| • 2024 – Present | Independent Director            | Thai Foods Group Public Company Limited         |
| • 2021 – 2023    | Chairman of the Audit Committee |   |
| • 2021 – 2023    | Chief Executive Chairman        | Bioscience Animal Health Public Company Limited |
| • 2021 – 2023    | Chief Operating Officer         | Thai Rubber Latex Group Public Company Limited  |
| • 2017 – 2024    | Director                        | Latex Systems Public Company Limited            |
| • 2017 – 2023    | Director                        | Worldflex Public Company Limited                |

##### **Other companies (5 EA.)**

- |                  |                       |  |
|------------------|-----------------------|--|
| • 2023 – Present | Chairman of the Board | Nong Bua Farm and Country Home Co., Ltd.         |
| • 2023 – Present | Chairman of the Board | Nong Bua Feed Mill Co., Ltd.                     |
| • 2023 – Present | Chairman of the Board | Able Asset Group Co., Ltd.                       |
| • 2020 – Present | Director              | BIS Group Holding Co., Ltd.                      |
| • 2020 – Present | Director              | Nutrition Improvement Co., Ltd.                  |
| • 2020 – 2024    | Director              | Pro Test Kit Co., Ltd.                           |
| • 2020 – 2024    | Director              | Feed and Ingredients Technological Hub Co., Ltd. |
| • 2020 – 2024    | Director              | Special Ingredient Services Co., Ltd.            |
| • 2017 – 2024    | Director              | Thai Rubber H.P.E.N.R. Co., Ltd.                 |
| • 2017 – 2021    | Director              | Thai Rubber Latex Group Public Company Limited   |

- Current position	Chairman of the Board
- History of attending the meeting in 2024	Annual General Meeting of Shareholders 1/1 time Board of Directors 6/6 time
- History of illegal acts in the past 10 years	-None-
- Qualification according to the laws and Does not have prohibited qualification according to the announcement of the SET	Yes
- Direct or indirect interest in any business in which the company is a party.	-None-

(The nominating director is not director or executive in other companies that may be conflict of interest with the Company and is an independent director who can give opinions independently and in accordance with relevant criteria.)

**2. Mr. Suchat Worrawutthangkool Age 50 Years****Director****Chief Executive Officer****Executive Committee****Risk Management Committee****Shareholding Proportion: (As of Dec 31, 2024)**

- direct 5.91%

- indirect 5.15

**Family relationship between executives: - None -****Duration of Directorship : 20 Years (1 Mar 2004 – Present)****Educational qualifications**

- Bachelor of Veterinary Science, Kasetsart University

**Director training history**

- Director Certification Program (DCP) Class 185, 2021

**work experience****Listed Company : (1 EA.)**

• 2004 – Present	Director	Bioscience Animal Health Public Company Limited
• 2024 – Present	Chief Executive Officer	Bioscience Animal Health Public Company Limited
• 2021 – Present	Executive Director	Bioscience Animal Health Public Company Limited
• 2021 – Present	Risk Management Committee	Bioscience Animal Health Public Company Limited
• 2020 – 2023	Chief Operating Officer	Bioscience Animal Health Public Company Limited
• 2018 – 2020	Executive Vice President	Bioscience Animal Health Public Company Limited

**Other companies (7 EA.)**

• 2024 – Present	Director	Pet Animal Data & Innovation Co., Ltd.
• 2023 – Present	Director	Beyond Animal Science Co., Ltd.
• 2020 – Present	Senior Executive Vice President	Nutrition Improvement Co., Ltd.
• 2020 – Present	Senior Executive Vice President	Special Ingredient Services Co., Ltd.
• 2020 – Present	Senior Executive Vice President	Pro Test Kit Co., Ltd.
• 2020 – Present	Director	Feed and Ingredients Technological Hub Co., Ltd.
• 2017 – Present	Director	BIS Group Holding Co., Ltd.
• 2014 – 2020	Senior Executive Vice President	Pro Test Kit Co., Ltd.
• 2012 – 2020	Senior Executive Vice President	Special Ingredient Services Co., Ltd.
• 2008 – 2020	Senior Executive Vice President	Nutrition Improvement Co., Ltd.

<b>- Current position</b>	Director
<b>- History of attending the meeting in 2024</b>	Annual General Meeting of Shareholders 1/1 time Board of Directors 6/6 time Risk management Committee 2/2 time
<b>- History of illegal acts in the past 10 years</b>	-None-
<b>- Qualification according to the laws and Does not have prohibited qualification according to the announcement of the SET</b>	Yes
<b>- Direct or indirect interest in any business in which the company is a party.</b>	-None-

(The nominating director is not director or executive in other companies that may be conflict of interest with the Company and is an independent director who can give opinions independently and in accordance with relevant criteria.)

**3. Mr. Rungroj Thavontanakul Age 47 Years****Director****Executive Committee****Risk Management Committee****Chief Administrative Officer****Company Secretary****Shareholding Proportion: (As of Dec 31 2024)**

- direct 2.59%

- indirect 2.31%

**Family relationship between executives: - None -****Duration of Directorship : 20 Years (1 Mar 2004 – Present)****Educational qualifications**

- Bachelor of Veterinary Science, Chulalongkorn University

**Director training history**

- Director Certification Program (DCP) Class 182, 2021

**work experience****Listed Company : (1 EA.)**

• 2004 – Present	Director	Bioscience Animal Health Public Company Limited
• 2021 – Present	Executive Director	Bioscience Animal Health Public Company Limited
• 2021 – Present	Risk Management Director	Bioscience Animal Health Public Company Limited
• 2022 – Present	Company Secretary	Bioscience Animal Health Public Company Limited
• 2023 – Present	Chief Administrative Officer	Bioscience Animal Health Public Company Limited
• 2020 – 2023	Chief Financial Officer	Bioscience Animal Health Public Company Limited

**Other companies (10 EA.)**

• 2024 – Present	Director	Pet Animal Data & Innovation Co., Ltd.
• 2023 – Present	Director	Beyond Animal Science Co., Ltd.
• 2020 – Present	Director	BIS Group Holding Co., Ltd.
• 2020 – Present	Director	Feed and Ingredients Technological Hub Co., Ltd.
• 2020 – Present	Director	Qualified Essence Suppliers & Traders Co., Ltd.
• 2020 – Present	Director	Pedex Co., Ltd.
• 2019 – Present	Director	Special Ingredient Services Co., Ltd.
• 2017 – Present	Director	BIS Group Holding Co., Ltd.
• 2014 – Present	Director	Pro Test Kit Co., Ltd.
• 2014 – Present	Director	Nutrition Improvement Co., Ltd.
• 2020 – 2021	Director	Intercons Three P Co., Ltd.
• 2020 – 2021	Director	Reco Pet Co., Ltd.
• 2018 – 2020	Assistant Executive Vice President	Bioscience Animal Health Public Company Limited
• 2018 – 2020	Assistant Executive Vice President	Nutrition Improvement Co., Ltd.

<b>- Current position</b>	Director
<b>- History of attending the meeting in 2024</b>	Annual General Meeting of Shareholders 1/1 time Board of Directors 6/6 time Risk management Committee 2/2 time
<b>- History of illegal acts in the past 10 years</b>	-None-
<b>- Qualification according to the laws and Does not have prohibited qualification according to the announcement of the SET</b>	Yes
<b>- Direct or indirect interest in any business in which the company is a party.</b>	-None-

(The nominating director is not director or executive in other companies that may be conflict of interest with the Company and is an independent director who can give opinions independently and in accordance with relevant criteria.)

**4. Mr. Poramase Kampak Age 50 Years****Director****Risk Management Committee****Shareholding Proportion: (As of Dec 31 2024)**

- direct 5.77%
- indirect 5.15%

**Family relationship between executives: - None -****Duration of Directorship : 20 Years (1 Mar 2004 – Present)****Educational qualifications**

- Bachelor of Veterinary Medicine, Kasetsart University

**Director training history**

- Director Certification Program (DCP) Class 185, 2021

**work experience****Listed Company : (1 EA.)**

- |                  |                          |   |
|------------------|--------------------------|---|
| ● 2004 – Present | Director                 | Bioscience Animal Health Public Company Limited |
| ● 2021 – Present | Risk Management Director | Bioscience Animal Health Public Company Limited |
| ● 2021 – 2024    | Executive Director       | Bioscience Animal Health Public Company Limited |
| ● 2020 – 2024    | Chief Operating Officer  | Bioscience Animal Health Public Company Limited |
| ● 2018 – 2020    | Executive Vice President | Bioscience Animal Health Public Company Limited |

**Other companies (6 EA.)**

- |                  |                          |  |
|------------------|--------------------------|--|
| ● 2025 – Present | Consultant               | Nutrition Improvement Co., Ltd.                  |
| ● 2020 – Present | Director                 | Nutrition Improvement Co., Ltd.                  |
| ● 2020 – Present | Director                 | Pro Test Kit Co., Ltd.                           |
| ● 2020 – Present | Director                 | Feed and Ingredients Technological Hub Co., Ltd. |
| ● 2019 – Present | Director                 | Special Ingredient Services Co., Ltd.            |
| ● 2018 – Present | Director                 | Ratchaburi King Mills Co., Ltd.                  |
| ● 2017 – Present | Director                 | BIS Group Holding Co., Ltd.                      |
| ● 2008 – 2020    | Executive Vice President | Nutrition Improvement Co., Ltd.                  |

<b>- Current position</b>	Director
<b>- History of attending the meeting in 2024</b>	Annual General Meeting of Shareholders 1/1 time Board of Directors 6/6 time Risk management Committee 2/2 time
<b>- History of illegal acts in the past 10 years</b>	-None-
<b>- Qualification according to the laws and Does not have prohibited qualification according to the announcement of the SET</b>	Yes
<b>- Direct or indirect interest in any business in which the company is a party.</b>	-None-

(The nominating director is not director or executive in other companies that may be conflict of interest with the Company and is an independent director who can give opinions independently and in accordance with relevant criteria.)

## Profiles of independent directors nominated by the Company as proxies for shareholders

Name	Age (year)	Position	Address	Conflict of interest in the proposed agenda
Mr. Rajata Rajatanavin	75	Chairman of the Audit Committee / Independent Director	1114 Soi Sukhumvit 101/1, Bang Chak, Phra Khanong, Bangkok, postal code 10260	-None-
Mr. Thaweesak Songserm	60	Member of the Audit Committee / Independent Director	63/1 Moo 10, Kamphaeng Saen, Kamphaeng Saen, Nakhon Pathom, postal code 73140	-None-

Special benefit extra from other Directors in this meeting: -None-

**Remark:** Profiles of Independent Directors are described in the 56-1 One report (Attachment 1)

Stamp duty 20 baht
--------------------------

## Proxy Form A.

(General form which is simple and uncomplicated)

Written at.....

Date.....Month..... Year.....

(1) I..... Nationality.....

Residing at No..... Road..... Tambol/Sub-district.....

Ampur/District..... Province..... Postal Code.....

(2) As a shareholder of Bioscience Animal Health Public Company Limited holding total of  
shares..... shares and having the right to vote equal to..... voted

(3) Hereby authorize

(1) Name..... age ..... year

Residing at No..... Road..... Tambol/Sub-district.....

Ampur/District..... Province..... Postal Code. .... or

(2) Name..... age ..... year

Residing at No..... Road..... Tambol/Sub-district.....

Ampur/District..... Province..... Postal Code ..... or

(3) Name..... age ..... year

Residing at No..... Road..... Tambol/Sub-district.....

Ampur/District..... Province..... Postal Code ..... or

Only one person as my representative to attend and vote on my behalf at the Annual General Meeting of Shareholders Wednesday, April 23, 2025 at 14:00 p.m. at Jupiter Room 13, 1st Floor, Challenger Building, IMPACT Muang Thong Thani or at will move to another date, time and place.

Any business performed by the proxy in that meeting shall be regarded as if I had done it myself in all respects.

Signed.....Proxy Grantor Signed .....Proxy Holder

(.....)

(.....)

Signed..... Proxy Holder Signed .....Proxy Holder

(.....)

(.....)

Remark

Shareholders who appoint proxies must authorize only one proxy to attend and vote at the meeting, the number of shares cannot be divided among several proxies to split their votes.

ปิดอากรแสตมป์

20 บาท

Duty Stamp 20 baht

สิ่งที่ส่งมาด้วยลำดับที่ 5

Enclosure 5

หนังสือมอบฉันทะ (แบบ ข)

Proxy Form (Form B)

เขียนที่ .....

Written at

วันที่ ..... เดือน ..... พ.ศ. ....

Date

Month

Year

(1) ข้าพเจ้า ..... อายุ ..... ปี สัญชาติ.....

I/ We ..... age ..... years, nationality

อยู่บ้านเลขที่.....

Residing at

ถนน ..... ตำบล/แขวง ..... อำเภอ/เขต .....

Road ..... Tambol/Khwaeng ..... Amphur/Khet

จังหวัด ..... รหัสไปรษณีย์.....

Province ..... Postal Code

(2) เป็นผู้ถือหุ้นของ บริษัท ไบโอซายน์ แอนิมัล เฮลท์ จำกัด (มหาชน) (“บริษัท”)

being a shareholder of Bioscience Animal Health Public Company Limited (“The Company”)

โดยถือหุ้นจำนวนทั้งสิ้นรวม ..... หุ้น และออกเสียงลงคะแนนได้เท่ากับ..... เสียง ดังนี้

holding the total number of shares .....and having the right to vote equivalent to votes as follows:

☐ หุ้นสามัญ ..... หุ้น ออกเสียงลงคะแนนได้เท่ากับ ..... เสียง

Ordinary share of ...shares ..... having the right to vote equivalent to .....votes

☐ หุ้นบุริมสิทธิ..... หุ้น ออกเสียงลงคะแนนได้เท่ากับ ..... เสียง

Preferred share of ....shares ..... having the right to vote equivalent to .....votes

(3) ขอมอบฉันทะให้ประธานกรรมการตรวจสอบและกรรมการอิสระ

I hereby authorize the Chairman of the Audit Committee and Independent Director

☐ ชื่อ นายรัชตะ รัชตะนาวิน อายุ 75 ปี อยู่บ้านเลขที่ 1114 ซอย สุขุมวิท 101/1  
Name Mr.Rajata Rajatanavin age 75 years, residing at 1114 Soi Sukhumvit 101/1  
ถนน - แขวง บางจาก เขต พระโขนง จังหวัด กรุงเทพมหานคร  
Road - Khwaeng Bang Chak Khet Phra Khanong Province Bangkok  
รหัสไปรษณีย์ 10260 หรือ  
Postal Code 10260 or

☐ ชื่อ นายทวีศักดิ์ ส่งเสริม อายุ 60 ปี อยู่บ้านเลขที่ 63/1 หมู่ 10  
Name Mr.Thaweesak Songserm age 60 years, residing at 63/1 Moo 10  
ถนน - ตำบล กำแพงแสน อำเภอ กำแพงแสน จังหวัด นครปฐม  
Road - Subdistrict Kamphaeng Saen District Kamphaeng Saen Province Nakhon Pathom  
รหัสไปรษณีย์ 73140 หรือ  
Postal Code 73140 or

☐ ชื่อ ..... อายุ ..... ปี อยู่บ้านเลขที่ .....  
Name ..... age ..... years, residing at .....  
ถนน ..... ตำบล/แขวง ..... อำเภอ/เขต .....  
Road ..... Tambol/Khwaeng ..... Amphur/Khet .....  
จังหวัด ..... รหัสไปรษณีย์ ..... หรือ  
Province ..... Postal Code ..... or

คนใดคนหนึ่งเป็นผู้แทนของข้าพเจ้า เพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้า ในการประชุม  
สามัญผู้ถือหุ้นประจำปี 2568 ในวันพุธที่ 23 เมษายน 2568 เวลา 14.00 น. ณ ห้องจูปีเตอร์ 13 ชั้น 1 อาคาร  
ชาเลนเจอร์ อิมแพ็ค เมืองทองธานี หรือที่จะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

Be my representative to attend the meeting and vote on my behalf at the 2025 Annual General Meeting  
of Shareholders on **Wednesday, April 23, 2025 at 14:00 p.m.** at Jupiter Room 13, 1st Floor, Challenger Building,  
IMPACT Muang Thong Thani. or on a later date, time and other places as well.

(4) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมครั้งนี้ ดังนี้  
I / We hereby appoint the proxy to vote for me / us in this meeting as follows:

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร  
(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be  
deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้  
(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

**วาระที่ 1      พิจารณารับรองรายงานการประชุมสามัญผู้ถือหุ้น ประจำปี 2567**

**Agenda 1      To consider and approve the meeting minutes of the 2024 Annual General Meeting of Shareholders**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

**วาระที่ 2      พิจารณารับทราบผลการดำเนินงานของบริษัท ในรอบปี 2567**

**Agenda 2      To consider and acknowledge the Company's operating performance for the year 2024**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

**วาระที่ 3      พิจารณานุมัติงบแสดงฐานะทางการเงิน งบกำไรขาดทุนเบ็ดเสร็จ และงบกระแสเงินสด สำหรับปีสิ้นสุด วันที่ 31 ธันวาคม 2567**

**Agenda 3      To consider and approve the statements of financial position, the statements of comprehensive income and cash flows for the year ended at December 31, 2024**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

วาระที่ 4 พิจารณานุมัติการจ่ายเงินปันผล และตั้งสำรองตามกฎหมายประจำปี 2567

Agenda 4 To consider and approve the dividend payment and set aside legal reserves for the year 2024

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

วาระที่ 5 พิจารณานุมัติแต่งตั้งกรรมการแทนกรรมการที่ต้องออกตามวาระ

Agenda 5 To consider and approve the appointment of directors to replace those who retired by rotation

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ การแต่งตั้งกรรมการทั้งชุด

Appointment of the whole group of directors

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

☐ การแต่งตั้งกรรมการเป็นรายบุคคล

Appointment of an individual director

1. นายวันชัย ศรีหิรัญรัมย์

Mr. Vanchai Sriherunrusmee

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

2. นายสุชาติ วรวิฑูรย์

Mr. Suchat Worawutthangkool

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

3. นายรุ่งโรจน์ ถาวรนากุล

Mr. Rungroj Thavontanakul

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

4. นายปรเมศวร์ ชำภักตร์

Mr. Poramase Kampak

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐งดออกเสียง

Abstain

**วาระที่ 6 พิจารณานุมัติค่าตอบแทนของกรรมการ ประจำปี 2568**

**Agenda 6 To consider and approve the directors' remuneration for the year 2025**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐งดออกเสียง

Abstain

**วาระที่ 7 พิจารณาแต่งตั้งผู้สอบบัญชี และกำหนดค่าสอบบัญชีประจำปี 2568**

**Agenda 7 To consider the appointment of the auditor and determine the audit fee for the year 2025**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐งดออกเสียง

Abstain

**วาระที่ 8 พิจารณาเรื่องอื่นๆ (ถ้ามี)**

**Agenda 8 Consider other issues (if any)**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐งดออกเสียง

Abstain

(5) การลงคะแนนเสียงของผู้รับมอบฉันทะในวาระใดที่ไม่เป็นไปตามที่ระบุไว้ในหนังสือฉันทะนี้ ถือว่าการลงคะแนนเสียงนั้น ไม่ถูกต้องและไม่ใช่เป็นการลงคะแนนเสียงของข้าพเจ้าในฐานะผู้ถือหุ้น

Voting of proxy holder in any agendas which are not specified in this proxy shall be considered as invalid and not my voting as a shareholder.

(6) ในกรณีที่ข้าพเจ้าไม่ได้ระบุความประสงค์ในการออกเสียงลงคะแนนในวาระใดไว้ หรือระบุไว้ไม่ชัดเจน หรือในกรณีที่ประชุมมีการพิจารณาหรือลงมติในเรื่องใดนอกเหนือจากเรื่องที่ระบุไว้ข้างต้น รวมถึงกรณีที่มีการแก้ไขเปลี่ยนแปลงหรือเพิ่มเติมข้อเท็จจริงประการใด ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

In case I/we have not specified my/our voting intention in any agendas or unclearly specified or in case the meeting considers or passes resolutions in any matters other than those specified above, including in case there is any amendments or additions of any facts, the proxy shall have the right to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

**กิจการใดที่ผู้รับมอบฉันทะได้กระทำไปในการประชุมนั้น ให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ**

Any acts performed by the proxy in this meeting shall be deemed to be the actions performed by myself/ourselves.

ลงนาม/Signed ..... ผู้มอบฉันทะ/Grantor  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

#### **หมายเหตุ/ Remark**

1. ผู้ถือหุ้นที่มอบฉันทะจะต้องให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุมและออกเสียงลงคะแนน ไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนเสียงได้

The shareholder appointing the proxy must authorize only one proxy to attend and vote at the meeting and may not split the number of shares to many proxies for splitting votes.

2. ผู้ถือหุ้นจะมอบฉันทะเท่ากับจำนวนหุ้นที่ระบุไว้ในข้อ (2) โดยไม่สามารถจะมอบฉันทะเพียงบางส่วนน้อยกว่าจำนวนที่ระบุไว้ในข้อ (2) ได้

The shareholder may grant the power to the proxy for all of the shares specified in Clause (2) and may not grant only a portion of the shares less than those specified in Clause (2) to the proxy.

3. ในกรณีที่มิวาระที่จะพิจารณาในการประชุมมากกว่าวาระที่ระบุไว้ข้างต้น ผู้มอบฉันทะสามารถระบุเพิ่มเติมได้ในใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ข) ตามแนบ

In case that any further agendas apart from specified above brought into consideration in the meeting, the proxy can state other agenda by using the Supplemental Proxy (Form B) as attached.

ใบประกอบแบบหนังสือมอบฉันทะ (แบบ ข)

Supplemental Proxy Form (Form B)

การมอบฉันทะในฐานะเป็นผู้ถือหุ้นของบริษัท ไบโอสายน์ แอนิมัล เฮลท์ จำกัด (มหาชน)

The proxy is granted by a shareholder of Bioscience Animal Health Public Company Limited.

ในการประชุมสามัญผู้ถือหุ้นประจำปี 2568 ในวันพุธที่ 23 เมษายน 2568 เวลา 14.00 น. ณ ห้องจูปีเตอร์ 13  
ชั้น 1 อาคารชาเลนเจอร์ อิมแพ็ค เมืองทองธานี หรือที่จะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

At the 2025 Annual General Meeting of Shareholders on **Wednesday, April 23, 2025 at 14:00 p.m.** at  
Jupiter Room 13, 1st Floor, Challenger Building, IMPACT Muang Thong Thani or as may be postponed to other  
date, time and location.

\*\*\*\*\*

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate  
in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate  
in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

ข้าพเจ้าขอรับรองว่า รายการในใบประจำต่อนี้ลงนามมอบฉันทะถูกต้องบริบูรณ์และเป็นความจริงทุกประการ  
I/We certify that the statements in this Supplemental Proxy Form are correct, completed and true in all respects.

ลงนาม/Signed ..... ผู้มอบฉันทะ/Grantor

(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy

(.....)

ปิดอากรแสตมป์

20 บาท

Duty Stamp 20 baht

สิ่งที่ส่งมาด้วยลำดับที่ 5

Enclosure 5

หนังสือมอบฉันทะ (แบบ ค)

Proxy (Form C)

(แบบที่ใช้เฉพาะกรณีผู้ถือหุ้นเป็นผู้ลงทุนต่างประเทศและแต่งตั้งให้คัสโตเดียน (Custodian) ในประเทศไทยเป็นผู้รับฝากและดูแลหุ้น) / Proxy Form C. (For foreign shareholders who have custodians in Thailand only)

เขียนที่ .....

Written at

วันที่ ..... เดือน ..... พ.ศ. ....

Date

Month

Year

(1) ข้าพเจ้า ..... สัญชาติ.....

I/ We ..... nationality

สำนักงานตั้งอยู่เลขที่.....

residing at

ในฐานะผู้ประกอบธุรกิจเป็นผู้รับฝากและดูแลหุ้น (Custodian) ให้กับ.....

Authorized Custodian of

(2) เป็นผู้ถือหุ้นของ บริษัท ไบโอสายน์ แอนิมัล เฮลท์ จำกัด (มหาชน) (“บริษัท”)

being a shareholder of Bioscience Animal Health Public Company Limited (“The Company”)

โดยถือหุ้นจำนวนทั้งสิ้นรวม ..... หุ้น และออกเสียงลงคะแนนได้เท่ากับ..... เสียง ดังนี้

holding the total amount of ..... shares and having the right to vote equals to ..... votes as follows:

☐ หุ้นสามัญ ..... หุ้น ออกเสียงลงคะแนนได้เท่ากับ ..... เสียง

Ordinary share ..... shares and having the right to vote equals to ..... votes

☐ หุ้นบุริมสิทธิ..... หุ้น ออกเสียงลงคะแนนได้เท่ากับ ..... เสียง

Preference share ..... shares and having the right to vote equals to ..... votes

(3) ขอมอบฉันทะให้ (ผู้ถือหุ้นสามารถมอบฉันทะให้กรรมการอิสระของบริษัทก็ได้ โดยมีรายละเอียดตาม **สิ่งที่ส่งมาด้วยลำดับที่ 4)**

Hereby appoint to (The shareholder may appoint an independent director of the Company to be the proxy, per details as shown in the **Enclosure 4)**

☐ ชื่อ ..... อายุ ..... ปี ..... อยู่บ้านเลขที่ .....

Name ..... age ..... years, residing at

ถนน ..... ตำบล/แขวง ..... อำเภอ/เขต .....

Road ..... Tambol/Khwaeng ..... Amphur/Khet

จังหวัด ..... รหัสไปรษณีย์..... หรือ

Province ..... Postal Code ..... or

☐ ชื่อ ..... อายุ ..... ปี ..... อยู่บ้านเลขที่ .....

Name ..... age ..... years, residing at

ถนน ..... ตำบล/แขวง ..... อำเภอ/เขต .....

Road ..... Tambol/Khwaeng ..... Amphur/Khet

จังหวัด ..... รหัสไปรษณีย์ .....

Province ..... Postal Code ..... or

คนใดคนหนึ่งเป็นผู้แทนของข้าพเจ้า เพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้า ในการประชุม  
สามัญผู้ถือหุ้นประจำปี 2568 ในวันพุธที่ 23 เมษายน 2568 เวลา 14.00 น. ณ ห้องจูปีเตอร์ 13 ชั้น 1 อาคารชาเลน  
เจอร์ อิมแพ็ค เมืองทองธานี เมืองทองธานี หรือที่แจ้งเปลี่ยนแปลงในวัน เวลา และสถานที่อื่นด้วย

Be my representative to attend the meeting and vote on my behalf at the 2025 Annual General Meeting  
of Shareholders on **Wednesday, April 23, 2025 at 14:00 p.m.** at Jupiter Room 13, 1st Floor, Challenger Building,  
IMPACT Muang Thong Thani. or on a later date, time and other places as well.

(4) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมครั้งนี้ ดังนี้

I / We hereby appoint the proxy to vote for me / us in this meeting as follows:

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be  
deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

**วาระที่ 1      พิจารณารับรองรายงานการประชุมสามัญผู้ถือหุ้น ประจำปี 2567**

**Agenda 1      To consider and approve the meeting minutes of the 2024 Annual General Meeting of Shareholders**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

**วาระที่ 2      พิจารณารับทราบผลการดำเนินงานของบริษัท ในรอบปี 2567**

**Agenda 2      To consider and acknowledge the Company's operating performance for the year 2024**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

**วาระที่ 3      พิจารณานุมัติงบแสดงฐานะทางการเงิน งบกำไรขาดทุนเบ็ดเสร็จ และงบกระแสเงินสด สำหรับปีสิ้นสุด วันที่ 31 ธันวาคม 2567**

**Agenda 3      To consider and approve the statements of financial position, the statements of comprehensive income and cash flows for the year ended at December 31, 2024**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

วาระที่ 4 พิจารณานุมัติการจ่ายเงินปันผล และตั้งสำรองตามกฎหมายประจำปี 2567

Agenda 4 To consider and approve the dividend payment and set aside legal reserves for the year 2024

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

วาระที่ 5 พิจารณานุมัติแต่งตั้งกรรมการแทนกรรมการที่ต้องออกตามวาระ

Agenda 5 To consider and approve the appointment of directors to replace those who retired by rotation

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ การแต่งตั้งกรรมการทั้งชุด

Appointment of the whole group of directors

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

☐ การแต่งตั้งกรรมการเป็นรายบุคคล

Appointment of an individual director

1. นายวันชัย ศรีหิรัญรัมย์

Mr. Vanchai Sriherunrusmee

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

2. นายสุชาติ วรวิฑูรย์

Mr. Suchat Worawutthangkool

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

3. นายรุ่งโรจน์ ถาวรนากุล

Mr. Rungroj Thavontanakul

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

4. นายปรเมศวร์ ชำภักตร์

Mr. Poramase Kampak

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

**วาระที่ 6 พิจารณานุมัติค่าตอบแทนของกรรมการ ประจำปี 2568**

**Agenda 6 To consider and approve the directors' remuneration for the year 2025**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

**วาระที่ 7 พิจารณาแต่งตั้งผู้สอบบัญชี และกำหนดค่าสอบบัญชีประจำปี 2568**

**Agenda 7 To consider the appointment of the auditor and determine the audit fee for the year 2025**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

**วาระที่ 8 พิจารณาเรื่องอื่นๆ (ถ้ามี)**

**Agenda 8 Consider other issues (if any)**

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

(5) การลงคะแนนเสียงของผู้รับมอบฉันทะในวาระใดที่ไม่เป็นไปตามที่ระบุไว้ในหนังสือฉันทะนี้ ถือว่าการลงคะแนนเสียงนั้น ไม่ถูกต้องและไม่ใช่เป็นการลงคะแนนเสียงของข้าพเจ้าในฐานะผู้ถือหุ้น

Voting of proxy holder in any agendas which are not specified in this proxy shall be considered as invalid and not my voting as a shareholder.

(6) ในกรณีที่ข้าพเจ้าไม่ได้ระบุความประสงค์ในการออกเสียงลงคะแนนในวาระใดไว้ หรือระบุไว้ไม่ชัดเจน หรือในกรณีที่ประชุมมีการพิจารณาหรือลงมติในเรื่องใดนอกเหนือจากเรื่องที่ระบุไว้ข้างต้น รวมถึงกรณีที่มีการแก้ไขเปลี่ยนแปลงหรือเพิ่มเติมข้อเท็จจริงประการใด ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

In case I/we have not specified my/our voting intention in any agendas or unclearly specified or in case the meeting considers or passes resolutions in any matters other than those specified above, including in case there is any amendments or additions of any facts, the proxy shall have the right to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

**กิจการใดที่ผู้รับมอบฉันทะได้กระทำไปในการประชุมนั้น ให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ**

Any acts performed by the proxy in this meeting shall be deemed to be the actions performed by myself/ourselves.

ลงนาม/Signed ..... ผู้มอบฉันทะ/Grantor  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

#### **หมายเหตุ/ Remark**

1. หนังสือมอบฉันทะแบบ ค. นี้ใช้เฉพาะกรณีที่ผู้ถือหุ้นที่ปรากฏชื่อในทะเบียนเป็นผู้ลงทุนต่างประเทศและแต่งตั้งให้คัสโตเดียน (Custodian) ในประเทศไทยเป็นผู้รับฝากและดูแลหุ้นให้เท่านั้น

Only foreign shareholders whose names appear in the registration book and have appointed a Custodian in Thailand can use the Proxy Form C.

2. หลักฐานที่ต้องแนบพร้อมหนังสือมอบฉันทะคือ

Evidence to be attached with this Proxy Form are:

(1) หนังสือมอบอำนาจจากผู้ถือหุ้นให้คัสโตเดียน (Custodian) เป็นผู้ดำเนินการลงนามในหนังสือมอบฉันทะแทน

Power of Attorney from the shareholder authorizing a Custodian to sign the Proxy Form on behalf of the shareholder.

(2) หนังสือยืนยันว่าผู้ลงนามในหนังสือมอบได้รับอนุญาตประกอบธุรกิจฉันทะคัสโตเดียน

(Custodian) Letter of certification to certify that a person executing the Proxy Form has obtained a permit to act as a Custodian.

3. ผู้ถือหุ้นที่มอบฉันทะจะต้องมอบฉันทะให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุม และออกเสียงลงคะแนนไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนได้

The shareholder appoint the proxy must authorize only one proxy to attend and vote at the meeting and may not split the number of shares to several proxies for splitting votes

4. วาระแต่งตั้งกรรมการสามารถแต่งตั้งกรรมการทั้งชุดหรือแต่งตั้งกรรมการรายบุคคล

In respect of the agenda as to the election of the directors, either the whole set of the nominated candidates or an individual nominee may be voted for

5. ในกรณีที่มิ่วาระที่พิจารณาในการประชุมมากกว่าวาระที่ระบุไว้ข้างต้น ผู้มอบฉันทะสามารถระบุเพิ่มเติมได้ในใบประจำต่อแบบหนังสือมอบฉันทะแบบ ค. ตามแนบ

In the case where there are any further agenda apart from those specified above brought into consideration in the meeting, the Grantor may use the Allege of the Proxy Form C. as attached

ใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ค)

Supplemental Proxy (Form C)

การมอบฉันทะในฐานะเป็นผู้ถือหุ้นของบริษัท ไบโอสายน์ แอนิมัล เฮลท์ จำกัด (มหาชน)

The proxy is granted by a shareholder of Bioscience Animal Health Public Company Limited.

ในการประชุมสามัญผู้ถือหุ้นประจำปี 2568 ในวันพุธที่ 23 เมษายน 2568 เวลา 14.00 น. ณ ห้องจูปีเตอร์ 13 ชั้น 1 อาคารชาเลนเจอร์ อิมแพ็ค เมืองทองธานี เมืองทองธานี หรือที่จะพึงเลื่อนไปในวัน เวลา และสถานที่อื่นด้วย

Behalf the the 2025 Annual General Meeting of Shareholders on **Wednesday, April 23, 2025 at 14:00 p.m.** at Jupiter Room 13, 1st Floor, Challenger Building, IMPACT Muang Thong Thani or on a later date, time and other places as well.

\*\*\*\*\*

วาระที่..... เรื่อง.....

Agenda No..... Subject : .....

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

☐ ไม่เห็นด้วย

☐ งดออกเสียง

Approve

Disapprove

Abstain

วาระที่..... เรื่อง.....

Agenda No..... Subject : .....

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

☐ ไม่เห็นด้วย

☐ งดออกเสียง

Approve

Disapprove

Abstain

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

☐ (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

☐ (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

☐ เห็นด้วย

Approve

☐ ไม่เห็นด้วย

Disapprove

☐ งดออกเสียง

Abstain

ข้าพเจ้าขอรับรองว่า รายการในใบประจำต่อหนังสือมอบฉันทะถูกต้องบริบูรณ์และเป็นความจริงทุกประการ I/We certify that the statements in this Supplemental Proxy Form are correct, completed and true in all respects.

ลงนาม/Signed ..... ผู้มอบฉันทะ/Grantor

(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy

(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy

(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy

(.....)

**Instructions on how to appoint a proxy, registration,  
evidences to be presented on the meeting date and how to vote.**

In case of shareholders attending the meeting in person

- 1) Shareholders who are individual persons of Thai nationality must present a valid government-issued identification document, such as an identity card. or official identification card or driver's license or passport. In case, if there is a change of name or surname, shareholders are requested to submit evidence as well.
- 2) Shareholders who are individual persons with foreign nationalities must present their passports or documents issued for use instead of a passport for registration.
- 3) If a shareholder changes his/her name or surname, evidence of the change of name or surname must be presented.

How to appoint a proxy

The company has sent 3 proxy forms as specified by the Department of Business Development. The Ministry of Commerce has specified according to the Notification of the Department of Business Development, Proxy Form (No. 5) B.E. 2550 as follows:

1. Form A is a universal proxy form, which is simple and uncomplicated.
2. Form B is a proxy form that prescribes various particulars detailed and clear proxy forms.
3. Form C is used only in case the shareholder is a foreign investor and appoints a custodian in Thailand to be a share custodian.

Shareholders who are unable to attend the Company's shareholders' meeting by yourself. Proxy can be done as follows:

1. Select only one of the above proxy forms as follows:
  - 1.1 General shareholders can choose to use only one Proxy Form A or Form B.

1.2 A shareholder whose name appears in the register book as a foreign investor and appoints a Custodian in Thailand to be a share depository and custodian can choose only one of the 3 forms (Form A, B or C).

2. Grant a proxy to any person according to the objectives of the shareholder or choose to appoint a director of the Company as "Mr. Ratchata Ratchatanavin, Chairman of the Audit Committee and Independent Director and Mr. Thaweesak Songserm Member of the Audit Committee and Independent Director" as the Company nominated as a proxy to attend such a meeting.

In case of granting a proxy to the Company's directors to vote on their behalf, please submit the proxy form and evidence before April 10, 2025 to the company secretary of Bioscience Animal Health Public Company Limited No. 479, 4th floor, Muang Thong Thani Village, Bond Street Road, Bang Phut Subdistrict, Pak Kret District, Nonthaburi Province 11120

3. Shareholders must appoint proxies equal to the number of shares they hold. Not able to appoint less than amount they hold, except for the custodian appointed by the shareholder who is a foreign investor to take care of shares according to Proxy Form C.

4. In voting for each agenda Shareholders or proxies have the right to vote, disagree or simply abstain only one voting can not be divided into parts (unless it is a Custodian vote).

5. Affix a duty stamp in the amount of 20 baht, crossed out and specify the date of making the proxy form to be correct and is legally binding. The company has facilitated the closure of stamp duty to the proxies who register to attend the meeting.

#### Meeting Registration

The Company will start a registration for attending the shareholders' meeting one hour before the start of the meeting by starting at 13:00 p.m. at Jupiter Room 13, 1st Floor, Challenger Building, IMPACT Muang Thong Thani, Popular Road, Ban Mai Subdistrict, Pak Kret District, Nonthaburi Province

Evidence required to be presented on the meeting date: Attendees are requested to present the following documents (depending on the case) before attending the meeting.

#### **Individual shareholders**

1. In case of shareholders attending the meeting in person

- Registration form (QR Code)

- A valid government-issued identification document such as a national ID card or government official card or driver's license or passport. In case of change of name or last name, shareholders are requested to submit evidence as well.

2. In case of appointing a proxy to attend the meeting instead

- Registration form (QR Code)

- Proxy form (Form A or Form B, either form) that is correctly and completely filled in and signed by the grantor and the proxy.

- A copy of the identification document issued by the government agency of the shareholder according to item no. 1 and the shareholder has signed certified true copy.

- An identification document issued by a government agency of the proxy same as item 1.

**Corporate shareholders**

1. In the event that the authorized person signing on behalf of the juristic person (director) attends the meeting in person.

- Registration form (QR Code).

- Identity document issued by the government agency of the representative of the juristic person same as in the case of individual person under item 1.

- A copy of the juristic person registration certificate of the shareholder certified true copy by the juristic person's representative (director) with a statement showing that the juristic person's representative who is an authorized attendee act on behalf of a juristic person which is a shareholder.

2. In case of proxy.

- Registration form (QR Code)

- Proxy form (Form A or Form B, either form) that has been correctly and completely filled in and signed of representatives of juristic persons (directors) who are grantors and proxies.

- A copy of the shareholder's juristic person registration certificate, certified true copy by the juristic person's representative (director) and showing that the juristic person's representative which signed the proxy form their Authority to act on behalf of a juristic person which is a shareholder.

- A copy of the identification document issued by the government agency of the representative of the juristic person (director) who is the grantor and have signed certified true name.

- An identity document issued by a government agency of the proxy, the same as in the case of an individual person under item 1.

3. In the case of shareholders who are investors abroad and appointed a custodian in Thailand as a recipient deposit and maintain shares

- Registration form (QR Code)

- Prepare documents and present documents as in the case of shareholders who are juristic persons No. 1 or No. 2.

- In the event that shareholders who are foreign investors authorize the Custodian to sign the proxy form instead, the following additional evidence must be submitted:

- 1) A Power of Attorney from a shareholder who is a foreign investor authorizing the Custodian to sign the proxy form on his/her behalf.

- 2) A letter confirming that the Custodian who signs the proxy form is authorized to do Custodian business. In case of the original document is not in English language, English translation is required and shareholders or juristic representatives the person have to certifies translation accuracy.

**How to vote in the shareholders' meeting.**

**1. Voting criteria**

(1) A shareholder has votes equal to the number of shares he holds. Each share is counted with one vote only, that is, agree, disagree, or abstain and could not split the vote into certain parts except for shareholders who are foreign investors and appoint a custodian in Thailand, being a share depository and custodian authorized a proxy to attend the meeting by using the proxy form C.

(2) If the grantor does not specify his or her intention to vote in the proxy form or not clearly stated proxies are entitled to consider and vote on their behalf.

## **2. Voting procedures for each agenda**

The chairman of the meeting will explain the details of voting methods to the meeting with the following guidelines.

(1) The chairman of the meeting will propose the shareholders to vote on each agenda. There will be asking for opinions in each agenda from the meeting whether any shareholder agrees, disagrees or abstains from voting, divided into 2 cases,

(a.) In case of shareholders attending the meeting in person or attending the meeting by proxy using power of Attorney Form A, who disagree with the Board of Directors' proposal or abstain on each agenda item to raise their hands to vote on such agenda and submit ballots which the Company was distributed when registering for the meeting by checking the box ☐ agree ☐ disagree or ☐ abstain in only one box of the ballot. In the event that no person raises their hand, it will be considered the shareholders approved the proposal of the Board of Directors.

(b.) In case of attendees who are authorized by shareholders using power of Attorney Form B or C in which the proxy has predetermined voting in every agenda, the Company will record the votes as specified by the proxy. Except in the case where the proxy grantor has not specified or clearly specified the purpose of voting in any agenda. Unless the grantor has not specified his or her intention to vote in any agenda or has not clearly specified it. The proxies can vote as they see fit, just like in the case of shareholders attending the meeting in person.

(2) Secret ballot may be done when at least 5 shareholders at the meeting request and the meeting resolves to have such a secret vote. The chairman of the meeting will determine the secret voting method and notify the meeting before the secret vote.

## **3. Resolution of the shareholders' meeting.**

The resolution of the shareholders' meeting shall consist of the following votes:

- In normal cases, the majority vote of the shareholders who attend the meeting and have the right to vote. If there are equal votes, the chairman of the meeting shall cast an additional vote as a deciding vote.

- In other cases where the law and/or the Company's Articles of Association have been stipulated differently from the normal case shall proceed accordingly. The chairman of the meeting will inform the shareholders in the meeting before voting on each agenda.

Any shareholder who has a special interest in any matter, do not vote on that matter and the chairman of the meeting may invite such shareholders to temporarily leave the meeting room.

#### **4. Vote counting and notification of vote counting results.**

When the voting result is known. The chairman will inform the result of the vote counting to the meeting.

Venue of the 2025 Annual General Meeting of Shareholders  
Bioscience Animal Health Public Company Limited

Wednesday, April 23, 2025 at 14:00 p.m.  
at Jupiter Room 13, 1st Floor, Challenger Building, IMPACT Muang Thong Thani  
Popular Road, Ban Mai, Pak Kret, Nonthaburi



**Principle 8****Encourage participation and communication with shareholders.**

The Board of Directors recognizes and places importance on the basic rights of shareholders. both as investors in securities and group owners, such as the right to buy, sell, transfer the securities they hold the right to receive profit sharing from the group of companies; the right to obtain sufficient information; The right to attend meetings to exercise voting rights at the shareholders' meeting to appoint or remove directors. appoint an auditor Approval of important transactions that affect the business direction of the Group and matters affecting the group of companies such as the allocation of dividends Prescribing or amending the Memorandum of Association and Articles of Association of the Group capital reduction or capital increase and approval of special items, etc.

In this regard, the Group has a mission to promote and facilitate the exercise of shareholders' rights as follows:

- (1) Information on date, time, place and agenda of the meeting is provided. With explanations and reasons supporting each agenda or supporting the requested resolution as specified in the notice of the Annual General Meeting of Shareholders and the Extraordinary General Meeting of Shareholders. Or in the documents attached to the meeting agenda completely sufficient for the shareholders' decision. and refrain from any action that limits the opportunity for shareholders to study the information of the Group.
- (2) Facilitate all groups of shareholders to fully exercise their rights to attend and vote at the meeting and refrain from Any action that limits the opportunity of shareholders to attend the meeting, such as using a place that is convenient for traveling a map showing the meeting venue will be attached in the invitation letter. Including choosing the right day and time and allocate sufficient time for the meeting. Including attending the meeting to vote should not be complicated or too costly.
- (3) before the date of the shareholders' meeting The Group of Companies will allow shareholders to submit comments, suggestions or inquiries prior to the meeting date. The criteria for sending questions in advance are clearly defined. And notify the shareholders together with the delivery of the invitation letter to the shareholders' meeting. And the Group will publish such guidelines through the Group's website.

- (4) Encourage shareholders to use proxy forms in which they can determine their voting direction. and nominate at least one independent director as an alternative for proxy of shareholders.
- (5) in the shareholders' meeting The chairman of the meeting will allocate appropriate time and the group of companies will allow shareholders to have the opportunity to express their opinions. Suggestions or questions related to any agenda freely before voting on any agenda.
- (6) Encourage all directors and senior executives of the Group to attend the shareholders' meeting to answer shareholders' questions.
- (7) Arrange for the resolution of the shareholders' meeting for each item in the event that the agenda contains several items, such as the agenda for the appointment of Company Directors.
- (8) The Group will support the use of ballots for important agenda items such as connected transactions. transaction of acquisition or disposition of assets, etc. for transparency and accountability in counting the voting results.
- (9) The Group will arrange for an independent person to assist in the counting or checking of votes for each agenda. And disclosed to the meeting and recorded in the minutes of the meeting.
- (10) after the shareholders' meeting is completed The Group will prepare minutes of meetings that accurately and completely record all important information. Important questions, opinions and suggestions will be recorded in the minutes of the meeting. for shareholders to be able to inspect. The minutes of the meeting were also published on the Group's website for shareholders to consider.
- (11) The Group will send a copy of the minutes of the shareholders' meeting to the SET within 14 days from the date of the shareholders' meeting.
- (12) Encourage the group companies to use technology in the shareholders' meeting. both registration of shareholders Score counting and display So that the conduct of the meeting can be done quickly, accurately and accurately.

In addition, the Board of Directors has prescribed the equitable treatment of all shareholders. Whether it is a major shareholder or a minor shareholder. Executive shareholders or non-executive shareholders Thai or foreign shareholders with the following guidelines:

- (1) Sending a meeting invitation letter with the agenda and opinions of the Board of Directors to the Stock Exchange of Thailand and disseminate the aforementioned meeting schedule through the Group's website in accordance with the rules, regulations and other relevant laws.
- (2) Determine criteria and procedures for minority shareholders to nominate candidates for the Company's directorship. Nominations can be made through the Nomination and Remuneration Committee in advance before the shareholders' meeting date. along with disseminating information for consideration of qualifications and consent of nominees.
- (3) Determine the criteria for minority shareholders to propose additional meeting agenda prior to the meeting date clearly in advance. To demonstrate fairness and transparency in considering whether to add an agenda proposed by minority shareholders or not.
- (4) Executive shareholders should not unnecessarily add to the agenda without notice in advance. Especially important agenda that shareholders must take time to study the information before making a decision.
- (5) In conducting each shareholder meeting The company will give equal opportunities to all shareholders. before the start of the meeting The chairman of the meeting will explain to the shareholders the rules and regulations used in the meeting. How to exercise your voting rights Voting rights according to each type of share and how to count the votes of shareholders who have to vote for each agenda.
- (6) In the agenda for the election of company directors The Group will support the election of individual directors.
- (7) Require company directors to report their interest in any meeting agenda at least before considering the relevant agenda in the Board of Directors' meeting and record such interest in the minutes of the Board of Directors' meeting. Including prohibiting company directors who have

significant interests in a manner that is unable to freely express opinions on related agendas from voting in the meeting on that agenda.

- (8) Establish written guidelines for safeguarding and preventing the use of internal information by the Group. And notify such guidelines to everyone in the group of companies to follow. All company directors and executives who have a duty to report their securities holdings according to the law are obligated to submit such reports to the company secretary. To present to the Board of Directors for acknowledgment in the next meeting and disclose in the annual report of the group of companies.